152 related articles for article (PubMed ID: 2049320)
1. Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma.
Gause A; Roschansky V; Tschiersch A; Smith K; Hasenclever D; Schmits R; Diehl V; Pfreundschuh M
Ann Oncol; 1991 Feb; 2 Suppl 2():43-7. PubMed ID: 2049320
[TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.
Viviani S; Camerini E; Bonfante V; Santoro A; Balzarotti M; Fornier M; Devizzi L; Verderio P; Valagussa P; Bonadonna G
Br J Cancer; 1998 Mar; 77(6):992-7. PubMed ID: 9528846
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome.
Ambrosetti A; Nadali G; Vinante F; Carlini S; Veneri D; Todeschini G; Morosato L; de Sabata D; Chilosi M; Maggi E
Cancer; 1993 Jul; 72(1):201-6. PubMed ID: 8508408
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
[TBL] [Abstract][Full Text] [Related]
5. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
Bien E; Balcerska A
Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of interleukin-2 receptor (CD 25) in patients with Hodgkin's disease, with special reference to age and prognosis.
Enblad G; Sundström C; Gronowitz S; Glimelius B
Ann Oncol; 1995 Jan; 6(1):65-70. PubMed ID: 7710984
[TBL] [Abstract][Full Text] [Related]
7. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Tura S; Papa G
Cancer; 1994 Sep; 74(6):1792-800. PubMed ID: 8082082
[TBL] [Abstract][Full Text] [Related]
8. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K; Chizuka A
Eur J Haematol; 2001 Jan; 66(1):24-30. PubMed ID: 11168504
[TBL] [Abstract][Full Text] [Related]
9. Detection of soluble IL-2 receptor in the serum and bone marrow of patients with minimal residual hematological malignancies: induction under therapy with IL-2.
Kandefer-Szerszeń M; Legieć W; Dmoszyńska A; Rzeski W
Arch Immunol Ther Exp (Warsz); 1997; 45(5-6):443-8. PubMed ID: 9437500
[TBL] [Abstract][Full Text] [Related]
10. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
[TBL] [Abstract][Full Text] [Related]
11. Soluble ICAM-1 in Hodgkin's disease: a promising independent predictive marker for survival.
Christiansen I; Enblad G; Kälkner KM; Gidlöf C; Glimelius B; Tötterman TH
Leuk Lymphoma; 1995 Oct; 19(3-4):243-51. PubMed ID: 8535215
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of soluble interlukin-2 receptor level at diagnosis on the outcome for patients with classical Hodgkin lymphoma treated with ABVD with or without radiotherapy.
Umino K; Fujiwara SI; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Ann Hematol; 2019 Sep; 98(9):2121-2129. PubMed ID: 31240469
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: a single center study in Japan.
Kono N; Kanda Y; Yamamoto R; Chizuka A; Suguro M; Hamaki T; Arai C; Matsuyama T; Takezako N; Miwa A; Togawa A
Leuk Lymphoma; 2000 Mar; 37(1-2):151-6. PubMed ID: 10721779
[TBL] [Abstract][Full Text] [Related]
14. [Significance of soluble interleukin-2 receptor alpha chain in the management of patients with malignant lymphoma: a multi-center study].
Ohno H; Ishikawa T; Kitajima H; Nomura S; Suzuki T; Konishi H; Ohno Y; Onishi R; Konaka Y; Arima N; Doi S; Nasu K; Takahashi T; Tsudo M; Fukuhara S; Uchiyama T
Rinsho Ketsueki; 2002 Mar; 43(3):170-5. PubMed ID: 11979748
[TBL] [Abstract][Full Text] [Related]
15. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
Goto N; Tsurumi H; Goto H; Shimomura YI; Kasahara S; Hara T; Yasuda I; Shimizu M; Murakami N; Yoshikawa T; Fukuno K; Takahashi T; Kito Y; Takami T; Moriwaki H
Ann Hematol; 2012 May; 91(5):705-714. PubMed ID: 22183251
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP.
Umino K; Fujiwara SI; Ikeda T; Toda Y; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Hematology; 2017 Oct; 22(9):521-526. PubMed ID: 28413914
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma.
Stasi R; Zinzani PL; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Papa G; Tura S
Br J Haematol; 1994 Dec; 88(4):770-7. PubMed ID: 7819101
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of the serum IL-2R level and Ga-67 scan findings in making a differential diagnosis between sarcoidosis and non-Hodgkin's lymphoma.
Kita T; Watanabe S; Yano F; Hayashi K; Yamamoto M; Iwasaki Y; Kosuda S
Ann Nucl Med; 2007 Nov; 21(9):499-503. PubMed ID: 18030581
[TBL] [Abstract][Full Text] [Related]
19. Analysis of regulation of T-cell responses by soluble inhibitory factors from the sera of patients with Hodgkin's disease.
Damle RN; Advani SH; Gangal SG
Int J Cancer; 1992 Jan; 50(2):192-6. PubMed ID: 1730512
[TBL] [Abstract][Full Text] [Related]
20. Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin's lymphoma: comparison with serum soluble interleukin-2 receptor values.
Tatsumi M; Sugahara H; Higuchi I; Fukunaga H; Nakamura H; Kanakura Y; Hatazawa J
Int J Clin Oncol; 2009 Apr; 14(2):150-8. PubMed ID: 19390947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]